Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1

Status

Recruiting 3Withdrawn 2

Sponsor Class

OTHER 73NIH 13NETWORK 7INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Head & Neck 1Genitourinary 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Lung Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 241Carboplatin 170Injections 139Paclitaxel 122Gemcitabine 118Bevacizumab 117Cisplatin 108Pemetrexed 80Docetaxel 80Cyclophosphamide 74Capecitabine 69Fluorouracil 67Oxaliplatin 65Fulvestrant 60Nivolumab 55Cetuximab 53fludarabine 52Leucovorin 51130-nm albumin-bound paclitaxel 50Dexamethasone 46Rituximab 41atezolizumab 38venetoclax 35toripalimab 35Drug Therapy 35enzalutamide 32Prednisone 32Letrozole 32Irinotecan 32durvalumab 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × X-Rays × Clear all
NCT07581184 2026-05-12

BActinium-1

Aktis Oncology, Inc.

Phase 1 Recruiting
138 enrolled
Genitourinary

Prostatic Neoplasms

NCT07020117 2026-04-21

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

Aktis Oncology, Inc.

Phase 1 Recruiting
150 enrolled
BreastHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

NCT07499674 2026-03-30

VISUALIZE-2

Vergent Bioscience, Inc.

Phase 3 Recruiting
132 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡